Larimar Therapeutics (LRMR) Enterprise Value (2016 - 2020)
Historic Enterprise Value for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to -$102.3 million.
- Larimar Therapeutics' Enterprise Value fell 2475.79% to -$102.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was -$102.3 million, marking a year-over-year decrease of 2475.79%. This contributed to the annual value of -$44.1 million for FY2019, which is 6268.27% up from last year.
- Per Larimar Therapeutics' latest filing, its Enterprise Value stood at -$102.3 million for Q3 2020, which was down 2475.79% from -$113.7 million recorded in Q2 2020.
- In the past 5 years, Larimar Therapeutics' Enterprise Value ranged from a high of -$44.1 million in Q4 2019 and a low of -$166.2 million during Q1 2016
- For the 5-year period, Larimar Therapeutics' Enterprise Value averaged around -$106.1 million, with its median value being -$104.7 million (2019).
- As far as peak fluctuations go, Larimar Therapeutics' Enterprise Value crashed by 8004.38% in 2016, and later surged by 6268.27% in 2019.
- Larimar Therapeutics' Enterprise Value (Quarter) stood at -$129.2 million in 2016, then grew by 21.01% to -$102.1 million in 2017, then fell by 15.69% to -$118.1 million in 2018, then skyrocketed by 62.68% to -$44.1 million in 2019, then crashed by 132.21% to -$102.3 million in 2020.
- Its Enterprise Value was -$102.3 million in Q3 2020, compared to -$113.7 million in Q2 2020 and -$63.9 million in Q1 2020.